HK Stock MarketDetailed Quotes

02500 VENUS MEDTECH-B

Watchlist
  • 5.620
  • 0.0000.00%
Market Closed Dec 10 16:08 CST
2.48BMarket Cap-4040P/E (TTM)

About VENUS MEDTECH-B Company

Hangzhou Qiming Medical Devices Co., Ltd. (“Qiming Medical”) is the leading enterprise in the field of minimally invasive interventional treatment of heart valves in China, and is committed to the development and commercialization of innovative medical devices in the field of structural heart disease. Qiming Medical was founded in 2009 and is located in Hangzhou National High-tech Industrial Development Zone (Binjiang). In 2014, the company won the national biomedical industry championship with the “Novel Biological Heart Aortic Valve Project” and stood out in this field. The company has four “No. 1 in China” titles: the first to begin and complete NMPA registered clinical research in China, the first is a cardiovascular device supported by the NMPA innovation channel, the first is a Chinese heart valve device that enters Europe for clinical implantation in humans, and the first is an enterprise approved to establish a heart valve research institute in China. On December 10, 2019, the company was successfully listed on the main board of the Hong Kong Stock Exchange with the stock code 02500. At present, Qiming Medical has established a comprehensive solution for structural heart disease, covering a complete pipeline of heart valve diseases such as aortic, pulmonary, mitral, and tricuspid valves, hypertrophic cardiomyopathy, hypertensive renal artery desympathetic ablation, and surgical ancillary products. By the end of August 2021, Qiming Medical had a total of 507 patents and patent applications, including 209 authorized invention patents. The main countries and regions of the layout include China, the United States, Europe, Japan, Canada, Russia, India, Brazil, etc. As a local innovative enterprise, Qiming Medical has received many awards and honors, including the 12th and 13th National Science and Technology Support Plan awards assessed by the Ministry of Science and Technology of China, the country's second batch of specialized, special and new “little giant” enterprises, China's Outstanding Patent Award, outstanding domestic medical equipment products, and national high-tech enterprises. In the future, Qiming Medical will focus on developing new materials, bionics, influence fusion technology and digital sensing directions, continuously update and iterate, and promote innovation to meet the needs of a wide range of doctors and patients. The company will not only act as a leader in the field of heart valves, but also expect the Qiming medical model to provide a strong reference for the development of China's innovative medical industry. Innovation leads the future, and Qiming Medical will continue to work on the development and marketization of innovative medical equipment for structural heart disease to accelerate innovation in China and benefit the world.

Company Profile

Symbol02500
Company NameVENUS MEDTECH-B
ISINCNE100003PJ8
Listing DateDec 10, 2019
Issue Price33.00
Shares Offered78.54M share(s)
FoundedJul 3, 2009
Registered AddressChina
Chairmandingxu hu
Secretaryweichao huang
Audit InstitutionZhonghui Certified Public Accountants
Company CategoryMainland registration of Mainland Individuals control
Registered OfficeRoom 311, 3 / F, Building 2, 88 Jiangling Road, Binjiang District, Hangzhou, China
Head Office and Principal Place of Business40th Floor, Dah Sing Finance Centre, 248 Queen's Road East, Wan Chai, Hong Kong
Fiscal Year Ends12-31
Employees778
MarketHong Kong motherboard
Phone(86)057186759022
Fax(86)057187772179
Emailinquiry@venusmedtech.com
Business Hangzhou Qiming Medical Devices Co., Ltd. is a Chinese company engaged in the R&D, manufacture and sale of minimally invasive medical equipment and auxiliary instruments and equipment for the treatment of valvular heart diseases. The company's main products include Venusa-Valve Systems, Venusa-Plus Systems, Venusa-Pilot Systems, Venusa-Valve Systems, TMVR Valves, TTVR Valves, Valvuloplasty Balloons V8/TAV8, and TriGuard3 cerebral embolism protection instruments.

Company Executives

  • Name
  • Position
  • Salary
  • haosheng lin
  • Executive Director, General Manager, Technical Director
  • 264.00K
  • liqiao ma
  • Executive Director
  • 46.00K
  • meirong liu
  • VP, Executive Director, Authorized Representative
  • 1.18M
  • ao zhang
  • Non-executive Directors
  • --
  • wei wang
  • Non-executive Directors
  • --
  • dingxu hu
  • Chairman, Independent Non-Executive Director, Remuneration Committee Chairman, Nomination Committee Members, Audit Committee Members
  • 360.00K
  • junhua gu
  • Independent Non-Executive Director, Chairman of the Nomination Committee, Audit Committee Members, Remuneration Committee Members
  • --
  • zhiwei sun
  • Independent Non-Executive Director, Chairman of the Audit Committee, Remuneration Committee Members, Nomination Committee Members
  • 360.00K
  • yue li
  • Shareholders' Representatives and Supervisors
  • 416.00K
  • changxi zhang
  • Chairman of the Supervisory Board, Employee Representative Supervisor
  • --
  • wei chen
  • Auditors
  • 113.00K
  • fei wang
  • Chief Financial Officer
  • --
  • bing zhu
  • Chief Financial Officer
  • --
  • weichao huang
  • Authorized Representative, Company Secretary
  • --
Heat List
HK
Overall
Symbol
Latest Price
% Chg

No Data